On this page
MNGIE
MNGIE is a serious inherited condition affecting multiple body systems, including the gut and nervous system. It is caused by genetic changes that disrupt mitochondrial activity, essential for energy production in cells.
Available at Jeen Health
Clinical tests that include this
Overview
Mitochondrial Neurogastrointestinal Encephalopathy (MNGIE) is a severe, progressive genetic disorder. It affects various parts of the body, most notably the gastrointestinal (GI) tract and the neurological system [PMID:33671234]. Individuals with MNGIE often experience significant digestive problems and neurological symptoms, which can severely impact their quality of life. The condition is considered rare, though its exact prevalence is not well established.
Symptoms & clinical features
Symptoms of MNGIE typically emerge during childhood or adolescence, although onset can vary. Gastrointestinal symptoms are prominent and often include chronic diarrhoea, abdominal pain, early satiety (feeling full quickly), nausea, vomiting, and significant weight loss due to malabsorption [PMID:24775494]. These digestive issues can lead to severe malnutrition. Neurological manifestations may include progressive weakness in the limbs, numbness, and tingling (peripheral neuropathy), as well as eye movement abnormalities (ophthalmoplegia), and sometimes white matter changes in the brain (leukoencephalopathy) detectable by imaging. Other potential symptoms can involve muscle weakness (myopathy) and hearing loss.
Video: Genetics 101
Affected organs
MNGIE primarily affects the gastrointestinal tract, leading to widespread dysmotility - meaning the muscles of the digestive system do not move food through properly. This can impact the oesophagus, stomach, and intestines. The peripheral nervous system is commonly affected, causing neuropathy that impacts sensation and movement in the limbs. The central nervous system, including the brain, can also be involved, leading to white matter changes. Muscles, eyes, and hearing can also be impacted due to the systemic nature of mitochondrial dysfunction.
Risks & severity
MNGIE is a progressive disorder, meaning symptoms typically worsen over time. The severity of symptoms can vary between individuals, even within the same family, but it is generally a severe condition. Untreated, MNGIE can lead to life-threatening complications, primarily from malnutrition and severe infection. Early diagnosis and management are crucial for improving outcomes and managing symptoms. There are currently no established population-wide prevalence figures for MNGIE.
Genetic causes
MNGIE is caused by genetic changes in the TYMP gene. This gene provides instructions for making an enzyme called thymidine phosphorylase (TP). This enzyme is crucial for breaking down certain nucleic acid building blocks, specifically thymidine and deoxyuridine. When the TYMP gene has pathogenic variants, the TP enzyme activity is significantly reduced or absent. This leads to an accumulation of thymidine and deoxyuridine in the body's tissues and fluids, including the mitochondria [PMID:24775494]. These elevated levels of nucleic acids are toxic to mitochondria, impairing their ability to produce energy effectively. Mitochondria are vital cellular components responsible for generating most of the energy needed for cellular function, particularly in high-energy demand organs like the brain and muscles. Their dysfunction underlies the wide range of symptoms seen in MNGIE.
- TYMP thymidine phosphorylase
Inheritance pattern
MNGIE is inherited in an autosomal recessive pattern. This means that an individual must inherit two altered copies of the TYMP gene - one from each parent - to develop the condition. People who inherit only one altered copy of the TYMP gene are called carriers. Carriers typically do not show symptoms of MNGIE themselves, but they can pass the altered gene copy on to their children. If two carriers have children together, there is a 25% chance with each pregnancy that their child will inherit two altered copies and develop MNGIE, a 50% chance the child will be a carrier, and a 25% chance the child will inherit two unaffected copies of the gene.
When both parents are carriers, each child has a 25% chance of being affected, 50% of being a carrier, and 25% of being unaffected.
Diagnosis & testing
A diagnosis of MNGIE is typically suspected based on characteristic clinical symptoms, particularly the combination of severe gastrointestinal and neurological problems. Initial investigations may include measuring levels of thymidine and deoxyuridine in plasma and urine; elevated levels are highly suggestive of MNGIE [PMID:33671234]. Reduced thymidine phosphorylase enzyme activity in white blood cells can also support a diagnosis. The definitive diagnosis is confirmed through genetic testing of the TYMP gene. This involves analysing a blood sample to identify pathogenic variants. In the UK, genetic testing for suspected MNGIE would typically be initiated through a referral to clinical genetics, often under an NHS Genomic Medicine Service R-code for mitochondrial disorders.
Management & lifestyle
Management of MNGIE focuses on symptom control and supportive care, as there is currently no cure. Nutritional support is paramount, often requiring specialised diets, oral supplements, or in severe cases, feeding through a tube (enteral or parenteral nutrition) to combat malnutrition and weight loss. Symptomatic treatments for gastrointestinal issues may be employed. Some individuals may be considered for liver transplantation, which can potentially restore thymidine phosphorylase activity and reduce toxic metabolite levels, though this is a complex procedure with significant risks. Haematopoietic stem cell transplantation (HSCT) has also been explored as a therapeutic option. These advanced treatments are generally only considered in specific clinical circumstances and after careful evaluation by a multidisciplinary team. Regular monitoring of neurological and gastrointestinal function is also important.
UK care pathway
In the UK, individuals suspected of having a rare genetic condition like MNGIE would typically be referred by their GP or specialist to a regional clinical genetics service. This service can provide expert diagnosis, genetic counselling, and access to NHS Genomic Medicine Service (GMS) pathways for genomic testing. For MNGIE, testing would fall under the GMS rare disease testing directory, likely within the mitochondrial disorders R-codes. Genetic counsellors can explain the inheritance pattern, implications for family members, and discuss reproductive options.
Frequently asked questions
What is the life expectancy for someone with MNGIE?
MNGIE is a severe, progressive condition, and without treatment, it can significantly shorten life expectancy, often into early adulthood. However, advances in supportive care and emerging treatments like liver or stem cell transplantation may improve outcomes for some individuals. The prognosis can vary depending on the severity of symptoms and response to management.
Can MNGIE be prevented?
As MNGIE is an inherited genetic condition, it cannot be prevented. However, for families with a known history of MNGIE, genetic counselling can provide information about the risks of passing on the condition and discuss reproductive options, such as preimplantation genetic diagnosis (PGD) or prenatal diagnosis.
Are there any clinical trials for MNGIE?
Research into MNGIE is ongoing, and clinical trials for new therapies may be available. Individuals interested in participating in trials should discuss this with their specialist clinical team, who can provide information on current research opportunities and eligibility criteria.
How does MNGIE affect daily life?
MNGIE can significantly affect daily life due to chronic digestive issues, often requiring careful dietary management or feeding support. Neurological symptoms like muscle weakness and numbness can also impact mobility and independence. Regular medical appointments and therapies are often necessary to manage symptoms and maintain quality of life.
Is MNGIE contagious?
No, MNGIE is not contagious. It is a genetic condition caused by specific changes in an individual's DNA, inherited from their parents. It cannot be transmitted from person to person through contact or any other means.
References
- Hirano M, Pitceathly RDS. Progressive external ophthalmoplegia. Handbook of clinical neurology. 2023. PMID: 36813323
- Hirano M, Carelli V, De Giorgio R. Mitochondrial neurogastrointestinal encephalomyopathy (MNGIE): Position paper on diagnosis, prognosis, and treatment by the MNGIE International Network. Journal of inherited metabolic disease. 2021. PMID: 32898308
- Orsucci D, Caldarazzo Ienco E, Rossi A. Mitochondrial Syndromes Revisited. Journal of clinical medicine. 2021. PMID: 33802970
- Finsterer J, Löscher WN, Wanschitz J. Orphan Peripheral Neuropathies. Journal of neuromuscular diseases. 2021. PMID: 32986679
- Du J, Liu F, Liu X. Lysosomal dysfunction and overload of nucleosides in thymidine phosphorylase deficiency of MNGIE. Journal of translational medicine. 2024. PMID: 38741129
- Filosto M, Cotti Piccinelli S, Caria F. Mitochondrial Neurogastrointestinal Encephalomyopathy (MNGIE-MTDPS1). Journal of clinical medicine. 2018. PMID: 30373120
- Finsterer J, Strobl W. Gastrointestinal involvement in neuromuscular disorders. Journal of gastroenterology and hepatology. 2024. PMID: 38859699
- Finsterer J. Mitochondrial ataxias. The Canadian journal of neurological sciences. Le journal canadien des sciences neurologiques. 2009. PMID: 19831121